Rosiglitazone Inhibits Acyl-CoA Synthetase Activity and Fatty Acid Partitioning to Diacylglycerol and Triacylglycerol via a Peroxisome Proliferator–Activated Receptor-γ–Independent Mechanism in Human Arterial Smooth Muscle Cells and Macrophages
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Rosiglitazone is an insulin-sensitizing agent that has recently been shown to exert beneficial effects on atherosclerosis. In addition to peroxisome proliferator–activated receptor (PPAR)-γ, rosiglitazone can affect other targets, such as directly inhibiting recombinant long-chain acyl-CoA synthetase (ACSL)-4 activity. Because it is unknown if ACSL4 is expressed in vascular cells involved in atherosclerosis, we investigated the ability of rosiglitazone to inhibit ACSL activity and fatty acid partitioning in human and murine arterial smooth muscle cells (SMCs) and macrophages. Human and murine SMCs and human macrophages expressed Acsl4, and rosiglitazone inhibited Acsl activity in these cells. Furthermore, rosiglitazone acutely inhibited partitioning of fatty acids into phospholipids in human SMCs and inhibited fatty acid partitioning into diacylglycerol and triacylglycerol in human SMCs and macrophages through a PPAR-γ–independent mechanism. Conversely, murine macrophages did not express ACSL4, and rosiglitazone did not inhibit ACSL activity in these cells, nor did it affect acute fatty acid partitioning into cellular lipids. Thus, rosiglitazone inhibits ACSL activity and fatty acid partitioning in human and murine SMCs and in human macrophages through a PPAR-γ–independent mechanism likely to be mediated by ACSL4 inhibition. Therefore, rosiglitazone might alter the biological effects of fatty acids in these cells and in atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, G., Elwood, F., McNally, J., Weiszmann, J., Lindstrom, M., Amaral, K., Nakamura, M., Miao, S., Cao, P., Learned, R. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200743200 · Cited by 319 · cited 1×
“First, hSMCs were treated with T0070907, a noncompetitive antagonist of PPAR- (23).”
MethodLewin, T. M., Kim, J.-H., Granger, D. A., Vance, J. E., & Coleman, R. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102036200 · Cited by 284 · cited 1×
“The membranes were then incubated overnight at 4°C with rabbit polyclonal anti-rat Acsl1 or Acsl4 antibodies (1:10,000) generated against the amino acid sequences MEVHELFRYFRMPELIDIR and EIHSMQSVEELGSKPENSSI, respectively (17).”
MethodSelf-citationThiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues
LeBrasseur, N. K., Kelly, M., Tsao, T.-S., Farmer, S. R., Saha, A. K., Ruderman, N. B., & Tomas, E. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2005 · Cited by 276 · cited 10×
“Therefore, the clinical effects of rosiglitazone, as well as other TZDs, may well be mediated not only by activation of PPAR- , but also by activation of AMPK and inhibition of ACSL4.”
BackgroundInfluential
Cited by
Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis
Kagan, V. E., Mao, G., Qu, F., Angeli, J. P. F., Doll, S., Croix, C. S., Dar, H. H., Liu, B., Tyurin, V. A., Ritov, V. B., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2238 · Cited by 3,029
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism
Ding, K., Liu, C., Li, L., Yang, M., Jiang, N., Luo, S., & Sun, L. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002533 · Cited by 396
Kanter, J. E., Kramer, F., Barnhart, S., Averill, M. M., Vivekanandan-Giri, A., Vickery, T., Li, L. O., Becker, L., Yuan, W., Chait, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111600109 · Cited by 309
Self-citationACSL family: The regulatory mechanisms and therapeutic implications in cancer
Quan, J., Bode, A. M., & Luo, X. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174397 · Cited by 306
Averill, M. M., Barnhart, S., Becker, L., Li, X., Heinecke, J. W., LeBoeuf, R. C., Hamerman, J. A., Sorg, C., Kerkhoff, C., & Bornfeldt, K. E. (2011) · Circulation · doi:10.1161/circulationaha.110.985523 · Cited by 155
Self-citationTateya, S., Rizzo, N. O., Handa, P., Cheng, A. M., Morgan-Stevenson, V., Daum, G., Clowes, A. W., Morton, G. J., Schwartz, M. W., & Kim, F. (2011) · Diabetes · doi:10.2337/db11-0255 · Cited by 138
Metadata
- Authors
- Askari, B., Kanter, J. E., Sherrid, A. M., Golej, D. L., Bender, A. T., Liu, J., Hsueh, W. A., Beavo, J. A., Coleman, R. A., & Bornfeldt, K. E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-04-01
- Volume
- 56
- Issue
- 4
- Pages
- 1143-1152
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2140096583
- Cited by
- 98
- References
- 4
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.